Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2023-09-19 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
独立董事对八届董事会第八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on the company's 2023 restricted stock incentive plan and its assessment management measures. It references compliance with laws and regulations, the company's articles, and internal governance rules. The document is a formal opinion related to board meeting matters and the submission of proposals to the shareholders' meeting. It does not contain financial statements or results, nor is it a report of financial performance or earnings. It is not a regulatory filing or announcement of a report publication. The content is focused on board/management information regarding governance and approval of incentive plans. Therefore, the document fits best under Board/Management Information (MANG). The document length is 2467 characters, which is relatively short but contains substantive content related to board opinions and management decisions, not just an announcement or certification.
2023-09-19 Chinese
第八届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the eighth meeting of the eighth board of directors of the company 华兰生物工程股份有限公司. It details voting results on several proposals related to a 2023 restricted stock incentive plan, including the plan draft, implementation assessment methods, and authorization for the board to handle related matters. The document also mentions that these proposals require shareholder approval at a general meeting. The text is a meeting resolution announcement rather than a full report or financial statement. It does not contain financial data or detailed management discussion but focuses on board decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is 2901 characters, which is consistent with a detailed board meeting resolution announcement rather than a full report or regulatory filing. Therefore, the appropriate classification is MANG with high confidence.
2023-09-19 Chinese
监事会关于关于公司2023年限制性股票激励计划相关事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion on the company's 2023 restricted stock incentive plan. It discusses compliance with laws and regulations, eligibility of incentive recipients, and the plan's alignment with company and shareholder interests. There is no financial data, audit report, or financial statements. It is not an announcement of voting results or a proxy solicitation. The document is a regulatory compliance and governance-related statement regarding a stock incentive plan. This fits best under Regulatory Filings (RNS) as it is a compliance verification document that does not fit other specific categories.
2023-09-19 Chinese
2023年限制性股票激励计划首次授予激励对象名单
Remuneration Information Classification · 95% confidence The document is a detailed list of recipients of a restricted stock incentive plan, including names, positions, and the number of shares granted. It focuses on the allocation of stock incentives to management and key personnel. This type of document is related to executive compensation and stock incentive plans, which falls under remuneration information rather than financial results, governance structure, or capital changes. It is not an annual report, earnings release, or regulatory filing. Therefore, the most appropriate classification is Remuneration Information (DEF 14A). The document length is short and specific to stock incentives, confirming it is not a general report or announcement.
2023-09-19 Chinese
安徽承义律师事务所关于华兰生物2023年限制性股票激励计划的法律意见书
Regulatory Filings Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a 2023 restricted stock incentive plan of a listed company, Hualan Biological Engineering Co., Ltd. It extensively discusses the legal compliance, eligibility, terms, conditions, and procedures related to the stock incentive plan. The document is not a financial report, earnings release, or regulatory announcement but a legal opinion specifically related to a stock incentive plan. This type of document is best classified under Regulatory Filings (RNS) as it is a legal opinion letter supporting a corporate action rather than a direct financial or management report, and it does not fit other categories like MANG or CAP which would cover management changes or capital updates. The document length and content confirm it is not a brief announcement or a report publication notice but a substantive legal opinion.
2023-09-19 Chinese
华兰生物工程股份有限公司股权激励计划自查表
Regulatory Filings Classification · 95% confidence The document is a detailed compliance self-checklist related to a company's equity incentive plan, covering regulatory compliance, eligibility of incentive recipients, plan details, performance metrics, and procedural adherence. It does not contain financial statements, earnings data, or audit opinions but focuses on regulatory and compliance aspects of the equity incentive plan. It is not an announcement or a brief summary but a comprehensive compliance report. This type of document aligns with regulatory filings related to compliance and governance but does not fit the categories of Annual Report, Audit Report, or Management Reports. Given the detailed compliance nature and absence of financial data, the best fit is Regulatory Filings (RNS). The document length is under 5,000 characters, but it is substantive and not merely an announcement, so it is not a Report Publication Announcement (RPA).
2023-09-19 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.